BioCentury
ARTICLE | Clinical News

AZP-531: Additional Phase II data

May 2, 2016 7:00 AM UTC

Top-line data from a double-blind, European Phase II trial in 47 patients with Prader-Willi syndrome and evidence of hyperphagia showed that once-daily subcutaneous AZP-531 for 2 weeks significantly i...